Formulation Strategies and Therapeutic Applications of Shikonin and Related Derivatives.

Shikonin anticancer antimicrobial nano formulations patents wound healing

Journal

Recent advances in drug delivery and formulation
ISSN: 2667-3886
Titre abrégé: Recent Adv Drug Deliv Formul
Pays: Netherlands
ID NLM: 101776133

Informations de publication

Date de publication:
2022
Historique:
received: 16 11 2021
revised: 11 01 2022
accepted: 11 01 2022
pubmed: 4 3 2022
medline: 26 5 2022
entrez: 3 3 2022
Statut: ppublish

Résumé

Shikonin and its derivatives are excellent representatives of biologically active naphthoquinones. A wide range of investigations carried out in the last few decades validated their pharmacological efficacy. Besides having magnificent therapeutic potential, shikonin and its derivatives suffer from various pharmacokinetic, toxicity, and stability issues like poor bioavailability, nephrotoxicity, photodegradation, etc. Recently, various research groups have developed an extensive range of formulations to tackle these issues to ease their path to clinical practice. The latest formulation approaches have been focused on exploiting the unique features of novel functional excipients, which in turn escalate the therapeutic effect of shikonin. Moreover, the codelivery approach in various drug delivery systems has been taken into consideration in a recent while to reduce toxicity associated with shikonin and its derivatives. This review sheds light on the essential reports and patents published related to the array of formulations containing shikonin and its derivatives.

Identifiants

pubmed: 35236278
pii: RADDF-EPUB-121240
doi: 10.2174/2667387816666220302112201
doi:

Substances chimiques

Naphthoquinones 0
shikonin 3IK6592UBW

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

55-67

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Kirandeep Kaur (K)

Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, 143005, India.

Atamjit Singh (A)

Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, 143005, India.

Hamayal Sharma (H)

School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.

Sanha Punj (S)

Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, 143005, India.

Neena Bedi (N)

Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, 143005, India.

Articles similaires

Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation

Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers.

Prashant Kesharwani, Kratika Halwai, Saurav Kumar Jha et al.
1.00
Chitosan Humans Folic Acid Nanoparticles Drug Carriers
Administration, Intranasal Humans Animals Nasal Mucosa Brain
Humans Neoplasms Cell Membrane Inflammation Nanoparticles

Classifications MeSH